Medical device supply chains: When more safety stock is the right resilience decision
In an article published on October 23, 2026, Supply Chain Dive reporter Susan Kelly examined how medical technology companies are changing their approach to supply chain resilience. Executives from Zoll Medical, Solventum and Vantive discussed inventory investments, semiconductor supply constraints, scenario planning and accountability at AdvaMed's MedTech Conference. Their remarks illustrate why the lowest possible inventory level is not necessarily the best operating decision when supply interruptions can affect access to essential medical products.
What the executives reported
Jon Rennert, chairman of Zoll Medical, described the importance of strategic inventory investments when semiconductor shortages and other disruptions threaten the availability of medical devices. The company has sought stronger relationships with semiconductor suppliers to explain the importance of its products, even though medical-device demand may be relatively small compared with other industries competing for the same components.
The inventory strategy carries a cost. Holding more components ties up capital and can expose the organization to obsolescence. But, according to Rennert's account, additional inventory can provide valuable time to respond when supply conditions deteriorate. The relevant decision is therefore not simply whether inventory is expensive, but whether the protection it provides justifies that expense for a particular product or component.
Heather Knight, chief commercial officer at Solventum, described the difficulty of creating supply redundancy across a portfolio of approximately 30,000 stock-keeping units. She emphasized prioritizing products on which customers depend most heavily and building resilience around those priorities. Her remarks also pointed to the need for continuing scenario planning as weather, cybersecurity, geopolitical and supplier disruptions change the operating environment.
Christopher Toth, CEO of Vantive, discussed the role of disaster recovery plans, integrated business planning and accountability for inventory held by regional operations. The reported approach connects decisions to increase inventory with responsibility for their financial consequences. This creates a more explicit balance between the cost of additional stock and the service protection it may provide.
These accounts describe the views and practices reported by the executives. They do not constitute an independently audited comparison of inventory policies, service outcomes or financial returns.
Why safety stock is a decision about consequences
Traditional inventory optimization often emphasizes the cost of holding stock against the probability and cost of a shortage. For medical technology companies, however, the consequences of unavailable products may include disrupted treatment, interrupted clinical procedures or delayed patient care. These effects cannot always be represented adequately by the immediate commercial value of the missing unit.
The resulting planning problem is asymmetric. Excess inventory generates visible costs through capital, storage, expiry and obsolescence. A shortage of a critical medical product may create much larger consequences that are less frequent, more difficult to monetize and potentially irreversible. Operations leaders must decide how to balance these unequal risks rather than treating all products as interchangeable inventory lines.
That does not justify maximizing buffers across the portfolio. The ability to substitute a product, the concentration of suppliers, component lead times, manufacturing recovery options and the seriousness of a service interruption all affect the appropriate level of protection.
Dataleo analysis: segment resilience before allocating capital
The central planning implication is that resilience should be differentiated by product and supply exposure. A credible policy can classify products by criticality, substitutability, supply concentration, lead-time variability, disruption recovery time and inventory obsolescence risk. These characteristics can then inform safety-stock targets, alternative sourcing investments and escalation thresholds.
For example, a component used in an essential device, supplied by a highly concentrated semiconductor market and requiring a long replacement qualification process may justify more inventory protection than a readily substitutable component with multiple qualified suppliers. The correct quantity still depends on actual demand, lead-time distributions, shelf life and the organization's ability to recover after disruption.
Operations leaders should distinguish between three forms of resilience investment: additional buffer stock, structural supply alternatives and faster response capability. They are not perfect substitutes. Inventory provides immediate coverage, additional qualified suppliers reduce concentration exposure, and scenario planning can accelerate decisions when conditions change. The effective combination depends on both cost and disruption characteristics.
A second requirement is to evaluate the assumptions behind any buffer. Historical demand and lead-time variability may not represent an extreme but plausible semiconductor shortage, a sudden supplier closure or a logistics interruption. Scenario-based decisions should therefore identify the disruption being protected against, the expected coverage period, the cost of protection and the residual exposure that remains.
Integrated business planning and decision accountability
Vantive's reported emphasis on integrated business planning is particularly relevant because a resilience decision crosses functional boundaries. Procurement may focus on supplier capability, planning on inventory coverage, commercial teams on service commitments, finance on working capital and operations on production continuity. Without a shared decision process, one team may create expensive buffers while another optimizes against them.
An effective IBP process can make the conflict visible. It should identify which products receive priority protection, which disruption scenarios justify action, who authorizes exceptional inventory investment and when those decisions should be reconsidered. Decision ownership matters because neither an inventory optimization engine nor a risk dashboard can determine an organization's acceptable exposure without an explicit business policy.
Regional accountability for inventory costs can create useful discipline, but it also presents a trade-off. If regional leaders are judged too narrowly on working capital, they may underinvest in protection whose benefits occur elsewhere in the network. Financial responsibility and service accountability must therefore be aligned rather than assigned independently.
What operations leaders should measure
A resilience strategy should not be judged only by total inventory or inventory turns. Relevant measures may include coverage of critical components, time to recover from a disruption, availability of qualified alternatives, exposure to single-source supply, service performance for critical products and the amount of working capital tied up in protective stock.
These indicators should be interpreted together. Higher inventory may be justified for a vulnerable critical product, while rising buffers across low-risk products could signal weak forecasting, unreliable supplier performance or a failure to challenge obsolete planning parameters. Resilience spending needs periodic review because product demand, supplier conditions, technology and regulatory requirements evolve.
There is also a risk of mistaking preparedness for proof of effectiveness. An organization may hold additional inventory and experience no shortage, but that alone does not demonstrate that the investment was optimal. Conversely, a disruption that exceeds the protection available does not necessarily mean the original decision was unreasonable. Evaluation requires examining the assumptions, available alternatives and information known when the decision was made.
Dataleo angle: resilience is a governed allocation of risk
The lesson from the executives' reported approaches is not that lean inventory is obsolete or that more stock is always safer. It is that supply chain planning must allocate resilience according to the consequences of failure. Operations leaders should use product criticality, supply vulnerability and credible disruption scenarios to decide where additional inventory, supplier alternatives or recovery capabilities are worth their cost.
The condition for value is an explicit planning policy that connects service priorities with inventory investment, assigns decision rights and revisits assumptions as circumstances change. The main failure mode is treating all inventory as either waste to eliminate or protection to accumulate, without distinguishing the risks being addressed. Integrated business planning should make the cost of resilience and the consequences of insufficient protection visible to the same decision-makers.
Evidence and limitations
This analysis draws on Susan Kelly's October 23, 2026 reporting from AdvaMed's MedTech Conference. The underlying evidence consists principally of executives' statements and described practices. The article does not provide a controlled comparison of different safety-stock policies, audited returns on resilience investment or independently established changes in patient outcomes. Dataleo's discussion of inventory segmentation, scenario design and accountability is an independent editorial interpretation, not a claim that the companies have implemented the particular framework described here.
Source and editorial credit
Original reporting: Susan Kelly, Medtech execs share secrets to building resilient supply chains, Supply Chain Dive, October 23, 2026. The reporting on the remarks of Zoll Medical, Solventum and Vantive executives is credited to Susan Kelly and Supply Chain Dive. The assessment of resilience allocation, safety-stock trade-offs and IBP decision responsibilities is Dataleo's independent analysis.
Illustration credit
The featured image is a thematic stock photograph sourced from Pexels and supplied under its free-use licensing terms. It does not depict Zoll Medical, Solventum, Vantive, their facilities, the conference or any verified resilience program. Its use does not imply endorsement by the photographer, Pexels or the companies discussed.